Modulation of Melanocyte Intercellular Adhesion Molecule-1 by Immune Cytokines  by Yohn, Joseph J et al.
Modulation of Melanocyte Intercellular Adhesion 
Molecule-1 by Immune Cytokines 
Joseph J. Yohn, Marguerite Critelli, M. Bradley Lyons, and David A. Norris 
Department of Dermatology University of Colorado School of Medicine and the Dermatology Service, the Department of Veterans 
Affairs Hospital, Denver, Colorado, U.S.A. 
Human melanocyte expression of intercellular adhesion 
molecule-1 (ICAM-1) with or without stimulation by inter-
feron gamma (IFN-G), tumor necrosis factor alpha (TNF-a), 
or interleukin-1-alpha (IL-1a), was measured utilizing direct 
immunofluorescence and fluorescence-activated cell sorting 
(FACS). Melanocytes grown in vitro expressed low levels of 
ICAM-1, which could be increased by exposing the cells to 
IFN -G, TN F-a, or IL-l a. Each cytokine caused an enhance-
ment of melanocyte I CAM-1 expression in a dose-dependent 
fashion. The lowest dose necessary to cause a significant in-
crease in melanocyte ICAM-1 expression was 1 U/ml 
IFN-G, 0.3 ng/ml TNF-a, or 3 U/ml IL-1a. Melanocytes 
were most sensitive to TNF-a stimulation, with the greatest 
C ell-surface molecules regulate cellular attachment, which is required for cell-cell interactions. Several related families of cell-surface molecules have been identified, each possessing unique properties that control cellular function and responses to the envi-
ronment. The integrins are a large family of cell-surface molecules 
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KGM: keratinocyte growth medium 
LAK: lymphokine-activated killer cells 
MGM: melanocyte growth medium 
PBS: phosphate-buffered saline 
TNF-a: tumor necrosis factor alpha 
TPA: 12-0-tetradecanoylphorbol 13-acetate 
levels of ICAM-1 expression following 30 ng/ml or more 
TNF-a. When IFN-G was added to melanocyte cultures in 
combination with TNF-a or IL-1a, there was an additive 
increase in ICAM-1 expression but no synergy was noted 
with the combined cytokines. To our knowledge, this is the 
first report of melanocyte ICAM-1 induction by TNF-a and 
IL-1a and by physiologically relevant doses of IFN-G. Be-
cause of the importance of ICAM-1 in the regulation of 
immune cell- target interactions, the study of ICAM-1 ex-
pression by melanocytes may help us to better understand 
immune mechanisms of melanocyte injury. j Invest Derma to! 
90:233-237, 1990 
that govern cell attachment to extracellular matrix, cell-cell adhe-
sion, complement binding, and phagocytosis [1]. Leukocyte func-
tion associated antigen (LFA-1), designated CD lla/CD 18, is a 
member of the integrin family and is expressed by all leukocytes (2]. 
LFA-1 mediates the non-antigen-specific cell contact essential for 
helper T cell function, interactions between antigen presenting cells 
and lymphocytes, cell mediated cytotoxicity and antibody depen-
dent cellular cytotoxicity (2]. The ligand for LFA-1 is intercellular 
adhesion molecule-1 (ICAM-1), recently designated CD 54 (3], 
which is expressed by keratinocytes, fibroblasts and endothelial cells 
[4- 6]. ICAM-1 expression by these cells can be modulated by inter-
feron gamma (IFN-G), tumor necrosis factor and interleukin 1 
[6-8]. 
In 1987, Tsujisaki et al (9) reported that a 96-kD melanoma-asso-
ciated antigen was expressed by normal human melanocytes and 
increased expression of this antigen was inducible by high-dose 
IFN-G. This antigen was later identified as ICAM-1 (10]. Due to 
the importance of cell attachment in immunologic reactions and the 
strengthening of lymphocyte-target interactions by the binding of 
ICAM-1 and LfA-1, identification offactors that control ICAM-1 
expression by melanocytes may allow a better understanding of the 
immunologic mechanisms of melanocyte damage. Herein we re-
port the effects of IL-1a and TNF-a on melanocyte ICAM-1 ex-
pression along with meticulous dose-response experiments with 
IFN-G. 
MATERIALS AND METHODS 
Materials Primary cell cultures from neonatal foreskins were 
grown in keratinocyte growth medium (KGM) purchased from 
Clonetics Inc. (San Diego, CA). Melanocyte growth medium 
(MGM) consisted of Ham's F-10 (Gibco, Inc., Grand Island, NY) 
supplemented with NaHC02 (1.2 g/1), HEPES (5.96 g/1), cholera 
toxin (2.5 nM), 12-0-tetradecanoylphorbol 13-acetate (TPA, 20 
ng/ml), isobutyl methylxanthine (IBMX, 100 nM) and calcium 
chloride purchased from Sigma Chemical (St. Louis, MO), and 
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penicillin/streptomycin/Fungizone and 5% fetal calf serum (FCS) 
purchased from Irvine Scientific (Santa Ana, CA). Plastic tissue 
culture flasks were obtained from Becton Dickinson Labware, Lin-
coln Park, NJ. Trypsin, geneticin, 1-5-isoquinolinesulfonyl-2-
methylpiperazine (H7), bovine serum albumin (BSA, Type V), 
paraformaldehyde, propidium iodide, para-phenylenediamine, and 
polymyxin B were purchased from Sigma Chemical Co., and Dul-
becco's phosphate-buffered saline (PBS) and 0.05% trypsin/0.02% 
ethylenediaminetetraacetic acid (EDTA) in Ha!1k's balanced salt 
solution were obtained from Irvine Scientific. 
Human recombinant interferon gamma (IFN-G) was obtained 
from Genentech (San Francisco, CA), human recombinant tumor 
necrosis factor alpha (TNF-cx), and interleukin-1 alpha (IL-lcx) 
were purchased from Genzyme Inc. (Boston, MA). Antibodies 
against TNF-cx and IL-1cx were obtained from Genzyme Inc. and 
anti-lFN-G was obtained from Interferon Sciences (New Bruns-
wick, NJ). 
Mouse monoclonal IgG 1 anti-ICAM-1 antibody was supplied by 
Robert Rothlein, Ph.D. (Boehringer Ingelheim, Ridgefield, CT), 
mouse monoclonallgG-1 anti-herpes simplex II antibody was ob-
tained from Cappel! Labs, and fluorescein-conjugated goat anti-
mouse IgG 1 antibody was purchased from Tago (Burlingame, CA). 
Cell Culture Neonatal foreskin melanocytes were grown by a 
method modified from that of Eisenger and Markos [11 ]. Briefly, 
the foreskins were trimmed of excess subcutaneous tissue and 
dermis and cut into 4 X 4 mm cubes. The cubes were placed in a vial 
containing sterile HEPES buffer with 0.25% trypsin for 2 h at 
37°C. The superficial epidermis was then separated from the stra-
tum basalis with forceps and the cells of stratum basalis collected by 
gentle scraping. The cells were then placed in HEPES bu!fer so.lu-
tion with 1 O% FCS, vortexed, and then recovered by centnfugatwn 
at 200 X g for 5 min. The cell pellet was resuspended in KGM and 
seeded onto a 25-cm2 culture flask. All cultures were fed twice 
weekly and incubated in a 37°~ humi~ified environment .. At con-
fluence, primary cultures were d!fferenttally trypsmtzed, wtth kera-
tinocytes passaged to new 75-cm2 plates and melanocytes passaged 
to new 75-cm2 plates and fed MGM. Fibroblast contamination of 
melanocyte cultures was eliminated by adding geneticin {1 00 
Jig/ ml) to each flask for the first 2 dafter passage. Melanocytes were 
further passaged 1 : 2 when s.oo/o c<?nfluent ~n.d confir~ed to be 
of melanocyte lineage by thetr abrltty to oxrdtze 3,4-dthydroxy-
phenylalanine to melanin and by reacting with anti-Sl 00 an-
tibodies [12] . 
Melanocytes from a total of 29 donors were used for experiments 
after second or third passage. ~ells were detached fron~ culture 
plates with trypsin/EDT A soluuon, pelleted, resuspended m KGM, 
and then seeded onto six-well plates at a density of 5.0 X 105 cells 
pet we ll for fluorescence-activated cell sorting (FACS) and 5.0 X 
104 cells per wel l on Lab-Tek chambers {Miles Laboratories, Naper-
ville, IL) for direct immunofluorescence. Melanocytes ;-vere grown 
in KGM (a serum-free medium without cholera to:cm, TPA, or 
IBMX) for 10 d prior to use in the ICAM-1 assays. Tl115 allowed .the 
cells to be free from exposure to serum or potent melanocyte mrto-
gens (13], which could affect ICAM-1 expression. All the melano-
cyte ICAM-1 assays were performed utilizing KG.M as cult~re me-
dium and all experiments were performed m duplrcate or tnplrcate. 
Induction of Melanocyte ICAM-1 Expression Sub-confluent 
melanocyte cu ltures growing in KGM were treated with IFN-G, 
TNF-cx, IL-1cx, TPA, and H7 for 24 h at the indicated concentra-
tions and combinations. After cytokine treatment, melanocytes 
were processed for direct immunofluorescence or FACS. A total of 
11 IFN-G, 11 TNF-a, and six IL-1a dose-response expenments 
were performed. Four TPA/IFN-G/H7 experiments were per-
formed. 
Immunocytochemical Localization of Melanocyte 
ICAM-1 Direct immunofluorescent staining for ICAM-1 was 
performed on melanocytes grown on Lab-Tek chamber .slides . 
Briefly, the cells were gently washed 111 PBS, mcubated With the 
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primary antibodies, anti-ICAM-1 (1: 1000 dilution), or anti-herp 
simplex II (negative control, 1: 100 dilution) for 1 hat 4 oc, washe~ 
with PBS, fixed in acetone, air dried, and then incubated with th~ 
fluorescein-conjugated secondary antibody (1: 50 dilution) at 4 o~ 
overnight. The slides were then washed with PBS and the celh 
counterstained with propidium iodide, dehydrated in increasin& 
concentrations of acetone/distilled water solutions, air dried, an~ 
mounted with paraphenylenediamine mounting medium. Melano, 
cyte ICAM-1 expression was analyzed, and the slides photographel\ 
using an Olympus BH2 epifluorescent microscope. 
For FACS analysis, melanocytes were removed from the cultur~ 
plates with trypsin/EDT A, the trypsin neutralized with 10o/o FCS, 
and the cells washed with HEPES buffer solution, pelleted by cen, 
trifugation, and then resuspended in PBS with 1.0% BSA, 0.1 % 
sodium azide at 4 o C for 1 h. The cells were incubated in 200 ,ul ot 
the primary monoclonal antibodies, anti-ICAM-1 (1 : 1000), ot 
anti-herpes simplex II (negative control, 1 : 1 00) at 4 c C for 1 h 
fixed in paraformaldehyde 2% in PBS, washed, and incubated i.n 
200 ,ul of the fluorescein-conjugated goat anti-mouse secondary an-
tibody (1: 50) at 4 oc overnight. Following incubation with th~ 
secondary antibody, the cells were resuspended in 2% paraformal-
dehyde and melanocyte expression ofiCAM-1 was measured by an 
EPICS V (Coulter Corp.) fluorescence-activated cell sorter. Fluo-
rescence-staining intensity for all the experiments was expressed as 
log-mean fluorescence (14], which is generated by computer pro-
gram (LogMean, Version 1.03, Denver, CO) and incorporates both 
percent positive and mean fluorescence values. This allowed for 
optimal comparison of fluorescent-staining results. Additionally, 
for each experiment, the anti- herpes simplex negative control clara. 
was subtracted from the experimental groups (delta log-mean), 
Thus the data presented herein is minus the background staining. 
Statistical Analysis Student t test was utilized to determine sra, 
tistical!y significant differences in ICAM-1 expression between th~ 
various treatment groups. 
RESULTS 
Induction Melanocyte ICAM-1 Expression As shown in Fia 
1, melanocytes expressed low levels ofiCAM-1 on their cell surfac~ 
and the expression could be increased by incubating the cells wit.1 
IFN-G for 24 h. Not all melanocytes stained with equal intensity 
following cytokine treatment. Some melanocytes fluoresced quit~ 
brightly, whereas others fluoresced less brightly. To compare mela-
nocyte ICAM-1 expression from different treatment groups, fluo-
Figure 1. JCAM-1 expression of neonatal foreskin melanocytes grown ill 
vitro. A: Baseline ICAM-1 expression (magnification X400). B: ICAM-1 
expression following 24-h incubation with 100 U/mllFN-G (magnific:h 
tion X400). 
VOL. 95, NO. 2 AUGUST 1990 
A 
c 
e 
1 
1 
• N 
u 
m 
b B 
e 
r 
0 
5 10 
Pos: 
M~an 
111 
15 
15 
52.04 
J.33 . 86 
zo 
211 
Fluorescence Intensity 
Loq-Mean 38 
25 
Loq-Mean 142 
25 
Figure 2. A representative FACS profile ofiFN-G-induced up-regulation 
of melanocyte ICAM-1. A: Baseline ICAM-1 expression. (Black profile: anti-
herpes simplex antibody negative control. White profile: anti-ICAM-1 anti-
body staining of non-cytokine-stimulated melanocytes [log-mean 38].) B: 
ICAM-1 expression following 24-h incubation with 10 U/ml IFN-G. 
(Black profile: anti-herpes simplex antibody negative control. White profile: 
anri-ICAM-1 antibody staining of melanocytes stimulated with 10 U/ml 
IFN-G [log-mean 142].) 
rescence intensity was measured by FACS analysis (Fig 2). Signifi-
cantly increased ICAM-1 expression, measured by FACS analysis, 
w as noted with 1.0 U/ml (p < 0.05) or greater IFN-G (Fig 3) and 
maximal expression occurred fo llowing treatment of melanocytes 
with 30 U/ml IFN-G (p < 0.001). No further significant increase 
in ICAM-1 expression could be induced with IFN-G doses above 30 
U /mi. A similar dose-response profile was noted following TNF-a 
treatment (Fig 3) but melanocytes appeared to be more sensitive to 
TNF-a stimulation with significant increases in ICAM-1 expres-
sion noted following melanocyte exposure to 0.3 ng/ml (p < 
0.005) or greater TNF-a. Maximal ICAM-1 induction followed 
melanocyte exposure to 30 ng/ml or more TNF-a (p < 0.001) . 
IL-1a, at dosages greater than 3 U /ml, was able to elicit melanocyte 
ICAM-1 expression significantly greater than baseline (p < 0.05), 
but was less effective than IFN-G or TNF-a at the dosages tested 
(Fig 3). 
When IFN-G (1 U/ml) was added to melanocyte cultures in 
combination with TNF-a (1 ng/ml), or IL-1 (3 U/ml) for 24 h 
there was an additive increase in melanocyte ICAM-1 expression 
but no synergy was noted with the combined cytokines (n = 5, data 
not shown). 
Specificity of melanocyte responses to immune cytokines was 
tested by preincubating the cytokines with blocking antibodies. In 
each case, antibodies against IFN-G-, TNF-a-, and IL-1a-
blocked induction of melanocyte ICAM-1 expression (n = 4, data 
not shown). 
To rule out any possible bacterial endotoxin contamination of the 
immune cytokines used, a series of experiments were performed 
using polymyxin B, which blocks the action of lipopolysaccharide 
endotoxins (15) . Melanocytes were treated with polymyxin B (10 
mg/ml) alone or with IFN-G, TNF-a, or IL-1a. No alteration of 
ICAM-1 expression was noted with polymyxin B treatment. 
Melanocyte treatment with TPA, 20 ngjml and 40 ng/ml, did 
not .cause enhancement of melanocyte ICAM-1 expression above 
baseline (Fig 4A) and although 20 ng/ml TPA combined with 
IFN-G caused slight enhancement of ICAM-1 expression, it was 
not statistically significant (p > 0.05). The TPA doses chosen were 
am ounts sufficient to significantly effect melanocyte growth and 
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protein synthesis (16). When the protein kinase C inhibitor, H7, 
was added to melanocyte cultures no change in baseline ICAM-·1 
expression was noted (Fig 4B). Moreover, i·'17 did not modify IFN-
G- induced melanocyte up-regulation of ICAM-1. 
DISCUSSION 
Treatment of human neonatal foreskin melanocytes with immune 
cytokines TNF-a, IL-1a, and IFN-G induced increased expression 
of ICAM-1 . To our knowledge, this is the first demonstration that 
the cytokines TNF-a and IL-1a induce ICAM-1 on human mela-
nocytes. In addition, our study confirms the results ofTsujisaki et al 
[9] who reported IFN-G stimulation of melanocyte ICAM-1 pro-
duction, but we have also shown that melanocytes respond to as 
little as 1.0 U/ml IFN-G. The lowest IFN-G dose tested by Tsuji-
saki was 250 U /mi. Interestingly, we also found that 24-h incuba-
tion with 30 U / ml IFN -G produced maximal stimulation of mela-
nocyte ICAM-1, a dose considerably lower than those used by 
Tsujisaki. This may be explained by the fact that in our studies, we 
utilized FACS analysis, a more sensitive assay than the mixed he-
madsorption assay utilized by Tsujisaki. Regardless, this study dem-
onstrates a more complete range of melanocyte responses to more 
biologically relevant doses of IFN-G. 
The addition of TP A, a very potent inducer of protein kinase C 
[17], had no effect on baseline melanocyte ICAM-1 expression nor 
any significant effect on IFN-G stimulation of ICAM-1. Further-
more, we noted no alteration of baseline or IFN-G-stimulated 
ICAM-1 expression following treatment of melanocytes with the 
protein kinase C inhibitor, H7. From these data we surmise that 
protein kinase C is not the second messenger system controlling 
melanocyte cell membrane ICAM-1 expression following IFN-G 
stimulation, nor does stimulation of protein kinase C cause up-regu-
lation of melanocyte ICAM-1. Similar results were reported by 
Temponi et al [10], who found that TPA did not modulate ICAM-1 
expression in human melanoma cell lines . The combination ofTPA 
plus IFN-G caused a slight increase in ICAM-1 expression above 
that of IFN-G alone. Although the difference in ICAM-1 expres-
sion was not statistically significant, it may indicate that stimulation 
of the protein kinase C pathway may indirectly effect ICAM-1 
expression in ways we do not as yet understand. Further work is 
necessary to elucidate the mechanisms underlying this phe-
nomenon. 
Melanocyte responsiveness to immune cytokine stimulation of 
ICAM-1 expression was not uniform as shown in Fig 1B and by the 
rather broad peaks of the FACS profiles (Fig 2) . This phenomenon 
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was also reported by Tsujisaki [?] and ~ay have functional signifi-
cance in vivo. LFA-1/ICAM-lmteracttons have been shown to be 
important for controlling cytotoxicity mediated by lymphokine-ac-
tivated killer (LAK) cells [18], cytotoxic lymphocytes (CTL) [19], 
and antibody-dependent cellular cytotoxicity (ADCC) [20). Mela-
nocytes that are more sensitive to ICAM-1- inducin~ signals may 
express a greater density ofiCAM-1 molecules on the1r cell surface, 
which would enhance effector cell adhesion. Th1s may augment 
antigen-specific or antigen- non-specific melanocyte killing. In-
deed, the level at which a melanocyte expresses adheswn molecules 
may, at least in part, govern its susceptibility to immune cytotoxic 
damage. . 
Melanocytes appear to be more sensitive in vitro to IFN-G stimu-
lation ofiCAM-1 expression than keratinocytes. In our l~boratory, 
keratinocyces require 5 U /ml or more IFN-G for s1gmficant m-
creases in ICAM-1 expression above baseline. Additionally, we have 
not noted induction of keratinocyte ICAM-1 by IL-l (21]. These 
differences in sensitivity to cytokine induction of ICAM-1 may be 
of importance if, during an inflammatory process, those melano-
cytes that are more sensitive to cytokine stimulation express in-
creased levels of ICAM-1, making them more susceptible to 
immune- effector-cell attachment. Increased effector-cell attach-
ment may allow for immune-cell trafficking into the epidermis, 
potentially making the melanocyte a "doorway" into the epidermis 
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prior to keratinocyte expression ofiCAM-1 during the early phase\ 
of some types of inflammation. Also, as stated above, increase~ 
expression ofiCAM-1 may result in melanocyte damage or killing 
This may be of great i~J.?~rtance ~n some cases of vitiligo in whic~ 
melano~ytes ~xpn;s~ _vmltg~ antigens [~2) . Elevated ICAM-1 ilj_ 
assoCiation with vmhgo anugen expressiOn would allow for anti\ 
gen-specifi.c immune- effector-cell attachment and melanocyte cy\ 
totoxicity. Furthermore, in individuals with circulating antibodie~ 
to vitiligo antigens, there may be enhancement of ADCC killing o~ 
those melanocytes with increased melanocyte ICAM-1 expression, 
ICAM-1 expression may also be involved in immune s urveillanc~ 
of malignant transformation of melanocytes. Melanoma cells ar~ 
known to express ICAM-1, the levels of which can be modulated h)\ 
IFN-G [10,23] . Transformed melanocytes that express melanoma, 
associated antigens may cause an antigen-specific immune response 
The expression of ICAM-1 on these cells may be enhanced b)~ 
keratinocyte- (24] or monocyte/macrophage-secreted IL-l an~ 
!NF-a (25) and T-cell-secreted IFN-G (26) in the inflammatol)1 
mfiltrate, thus makmg them efficient targets for CTL, LAK. 
ADCC, or natural killer cells. 1 
Finally, immune cytokines secreted by T cells and monocytesf 
macrophages in the infiltrates of non-melanocyte- specific inflam, 
matory reactions, such as discoid lupus erythematosus, may induce) 
increased melanocyte ICAM-1 expression, making them targets fo~ 
antigen-non-specific cytotoxicity by activated killer cells. This 
may be a mechanism by which "innocent bystander" melanocyte~ 
are destroyed during an inflammatory process causing post-inflam, 
matory hypopigmentation. 
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